Andrew
Shales

Andrew Shales is an experienced pharmaceutical and diagnostics leader with a deep commercial background and broad organizational experience. From start-up organizations to established companies with mega-brands, Mr. Shales’ specific expertise includes development planning, analysis/modeling, strategic planning and commercial execution. He has been central in many business development closings and has presented to capital markets on multiple occasions. Andrew has demonstrated success building compliant, high performance multi-disciplinary teams and working in collaboration with multiple global partners. He is a situational leader focused on high priority activities that deliver committed results.

Mr. Shales led pre-launch and launch marketing planning and execution for the anticonvulsant KEPPRA® (levetiracetam). KEPPRA is often cited as the product that established UCB Pharma in the U.S. pharmaceutical market. He also conducted payer research and wrote the initial marketing plan for Exact Sciences’ COLOGUARD® colorectal cancer screening test.

In total, Andrew launched or relaunched more than twenty-five ethical pharmaceutical brands and led three startup pharma companies from inception to profitability by their third full year of operations. He also ran his own consulting company, Shales & Associates, where two of his clients hired him directly to lead the functions he was working on.

Mr. Shales holds a bachelor’s degree from King’s College in Wilkes-Barre, PA and is currently enrolled part-time in the MSJ program in Pharmaceutical and Medical Device Law and Compliance at Seton Hall Law School. He also serves as a Senior Advisor to the medical device company Optovibronex.